Abstract

Enterobactin (Ent) is a highly conserved and important siderophore for the growth of many Gram-negative bacterial pathogens. Therefore, targeting Ent for developing innovative intervention strategies has attracted substantial research interest in recent years. Recently, we developed a novel Ent conjugate vaccine that has been demonstrated to be effective for controlling Gram-negative pathogens using both in vitro and in vivosystems. In particular, active immunization of chickens with the Ent conjugate vaccine elicited strong immune responses and significantly reduced intestinal colonization of Campylobacter jejuni, the leading foodborne bacterial pathogen. Given that hyperimmune egg yolk immunoglobulin Y (IgY) has been increasingly recognized as a promising and practical non-antibiotic approach for passive immune protection against pathogens in livestock, in this study, we assessed the efficacy of oral administration of broiler chickens with the anti-Ent hyperimmune egg yolk powder to control C. jejuni colonization in the intestine. However, supplementation of feed with 2% (w/w) of anti-Ent egg yolk powder failed to reduce C. jejuni colonization when compared to the control group. Consistent with this finding, the ELISA titers of the specific IgY in cecum, ileum, duodenum, gizzard, and serum contents were similar between the two groups throughout the trial. Chicken intestinal microbiota also did not change in response to the egg yolk powder treatment. Subsequently, to examine ex vivo stability of the egg yolk IgY, the chicken gizzard and duodenum contents from two independent sources were spiked with the egg yolk antibodies, incubated at 42 °C for different lengths of time, and subjected to ELISA analysis. The specific IgY titers were dramatically decreased in gizzard contents (up to 2048-fold) but were not changed in duodenum contents. Collectively, oral administration of broiler chickens with the anti-Ent egg yolk powder failed to confer protection against intestinal colonization of C. jejuni, which was due to instability of the IgY in gizzard contents as demonstrated by both in vivo and ex vivo evidence.

Highlights

  • A hen’s egg contains a large quantity of egg yolk antibodies, which are transferred from serum to yolk during egg formation

  • With the aid of the production of a high titer of anti-Ent egg yolk immunoglobulin Y (IgY) [14], in this study, we examined the efficacy of oral administration of the anti-Ent egg yolk IgY for C. jejuni control in broiler chickens

  • Given the harsh environment encountered by egg yolk IgY in the GI tract, the in vivo availability of egg yolk IgY is a key issue that needs to be addressed for data interpretation and understanding the mechanism of the passive immunity conferred by egg yolk IgY

Read more

Summary

Introduction

A hen’s egg contains a large quantity of egg yolk antibodies (immunoglobulin Y, IgY), which are transferred from serum to yolk during egg formation. Egg yolk IgY has drawn considerable interest as a passive immune agent and a promising alternative to antibiotics due to several unique features [2,3]. A hen can produce 15–30 g of egg yolk IgY yearly with 2–10% being antigen-specific. Numerous studies have been conducted to develop antigen-specific egg yolk IgY for passive immune protection of food animals, aquaculture, and humans against diverse microbial pathogens, showing partial successes of this approach [1,2]. Developing pathogen-specific egg yolk IgY is a promising approach to prevent and control microbial infections in food animals for enhanced animal health and food safety [1,3]

Methods
Findings
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call